Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Cash & Equivalents (2016 - 2025)

Veracyte (VCYT) has disclosed Cash & Equivalents for 14 consecutive years, with $362.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 51.65% to $362.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $362.6 million through Dec 2025, up 51.65% year-over-year, with the annual reading at $362.6 million for FY2025, 51.65% up from the prior year.
  • Cash & Equivalents hit $362.6 million in Q4 2025 for Veracyte, up from $315.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $362.6 million in Q4 2025 to a low of $153.4 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $223.0 million across 5 years, with a median of $205.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 122.14% in 2021 and later crashed 53.15% in 2022.
  • Year by year, Cash & Equivalents stood at $173.2 million in 2021, then decreased by 10.94% to $154.2 million in 2022, then surged by 40.33% to $216.5 million in 2023, then rose by 10.46% to $239.1 million in 2024, then surged by 51.65% to $362.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for VCYT at $362.6 million in Q4 2025, $315.6 million in Q3 2025, and $219.5 million in Q2 2025.